Ask AI
ProCE Banner Activity

MISSION POSSIBLE: Elevating Risk Recognition, Treatment Decisions, and Pancreatitis Prevention in Severe Hypertriglyceridemia

Slideset

Patients’ triglyceride levels will determine your clinical priority in managing severe hypertriglyceridemia (sHTG), whether it is atherosclerotic cardiovascular disease (ASCVD) or acute pancreatitis risk reduction. Access these slides to learn best practices in recognizing and diagnosing patients with sHTG, assessing their ASCVD and acute pancreatitis risk, initiating foundational therapy, and escalating to ApoC-III–targeted agents through coordinated, multidisciplinary care.

Released: November 05, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Target Audience

This activity is intended for cardiology physicians, NPs, PAs, and other healthcare professionals involved in the care of patients with sHTG.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with severe hypertriglyceridemia (sHTG) through appropriate risk assessment, lipid evaluation, and recognition of key clinical indicators

  • Assess current and emerging treatment approaches for severe hypertriglyceridemia, incorporating patient-specific cardiovascular risk factors and comorbidities

  • Apply guideline-based management strategies to optimize triglyceride lowering, improve cardiometabolic health, and reduce the likelihood of acute pancreatitis in patients with sHTG